Amryt Pharma Holdings Ltd
LSE:AMYT
Amryt Pharma Holdings Ltd
Operating Income
Amryt Pharma Holdings Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
Operating Income
-$45.4m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£7.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$257m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$622m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is Amryt Pharma Holdings Ltd's Operating Income?
Operating Income
-45.4m
USD
Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Operating Income amounts to -45.4m USD.
What is Amryt Pharma Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-94%
Over the last year, the Operating Income growth was -39%. The average annual Operating Income growth rates for Amryt Pharma Holdings Ltd have been -40% over the past three years , -94% over the past five years .